Status:
ACTIVE_NOT_RECRUITING
Neurofeedback for Borderline Personality Disorder
Lead Sponsor:
Kymberly Young
Collaborating Sponsors:
AE Foundation
Conditions:
Borderline Personality Disorder
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.
Detailed Description
We will assess the treatment effects of real-time fMRI neurofeedback in adults with borderline personality disorder. This is an experimental longitudinal design where participants will be followed eve...
Eligibility Criteria
Inclusion
- right-handed adults (ages 18 - 55) with a primary diagnosis of Borderline Personality Disorder according to diagnostic criteria in the Structured Interview for DSM Personality Disorders
- must be able to give written informed consent prior to participation
- unmedicated or stable on an SSRI antidepressant regime (at least 3 weeks to ensure symptoms are stable)
- English speaking
Exclusion
- have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder
- Current moderate or severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention.
- have a history of traumatic brain injury
- are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)
- are currently pregnant or breast feeding
- are unable to complete questionnaires written in English
- current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population
- have a DSM-5 diagnosis of psychotic or organic mental disorder
- have any eye problems or difficulties in corrected vision.
- Serious suidicial ideation
Key Trial Info
Start Date :
September 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05398627
Start Date
September 2 2022
End Date
April 30 2026
Last Update
November 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213